{"id":"W3026903046","doi":"10.1158/1078-0432.ccr-19-4121","title":"EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Genomics; Ozmosis Research (Canada); Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Olaparib; Ovarian cancer; Medicine; PARP inhibitor; Oncology; Clinical trial; Internal medicine; Phases of clinical research; Open label; Cancer; Cancer research; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004188747,0.000277341,0.001093555,0.0001296122,0.0002611065,0.00008345114,0.0002821296,0.0004728453,0.001285618],"category_scores_gemma":[0.001448991,0.0002345151,0.0002736668,0.0005004155,0.001266151,0.0003160179,0.0002679702,0.001271013,0.000008370742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001510928,"about_ca_system_score_gemma":0.001740873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009941899,"about_ca_topic_score_gemma":0.00008686982,"domain_scores_codex":[0.9942828,0.000778546,0.002040962,0.001100949,0.001175006,0.0006216764],"domain_scores_gemma":[0.9957126,0.001546441,0.0003564403,0.0004039942,0.001171223,0.0008093027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7895216,0.0148143,0.005790445,0.0006438408,0.0003690317,0.00003593486,0.0009254917,0.000003957095,0.006766545,0.0001594922,0.01373601,0.1672334],"study_design_scores_gemma":[0.8546994,0.05002972,0.003794509,0.002177079,0.0003352934,0.000004352758,0.0001106097,0.007644667,0.005471082,0.0007259474,0.07452828,0.0004790997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9482849,0.002675118,0.001146973,0.03691716,0.001064042,0.008640682,0.0009018842,0.00006088869,0.0003084002],"genre_scores_gemma":[0.983943,0.0015548,0.003578159,0.003016554,0.003955021,0.003566479,0.0001286315,0.00007642555,0.0001809472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1667543,"threshold_uncertainty_score":0.9996274,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5458711143040862,"score_gpt":0.62167981321802,"score_spread":0.07580869891393383,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}